EpCAM (CD326) overexpression is an early event during cancer progression in some types of tumors such as prostate and lung cancer, as well as in CRC (Miranda-Lorenzo et al., 2014; Pitule et al., 2014; Rowehl et al., 2014; Liu et al., 2014a,b). Here, EPCAM is linked to lung cancer.